Drinabant

屈那班

Report date: 2024/12/30 16:42:41
NME

Base Information

Drug NameDrinabant
Drug Alias Name屈纳班drinabantum德立纳班OPNT-004AVE-1625 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCannabinoid CB1 receptor antagonists
TargetsCannabinoid CB1 receptor
Therapy Area/IndicationsSchizophreniaObesityDyslipidemias +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[6] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOpiant PharmaceuticalsSanofiIndivior PLC
Active IndicationsN/A
Inactive IndicationsSchizophreniaObesityDyslipidemias +[4] 

Other Information

ATC CodeN/A
Related LinksWikipedia